Finding variants in the human genome
New findings show the value of genetic studies across human populations and the value of the latest DNA sequencing technologies to interrogate genetic variation. The results, from the latest phase of the international HapMap Project, are reported in Nature.
The researchers’ extensive study of genetic variation in multiple populations will form a framework for future genetic studies of variation and disease: their findings highlight the need to examine various populations in order to tease out the widest collection of genetic variants, as well as the requirement to deploy sequencing technologies to find as many variants as possible.
The HapMap Project seeks to identify signposts on the human genome that will simplify the search for important genetic variants. In the latest phase – HapMap 3 – the researchers looked for variants across the genome in 1184 samples from 11 populations. They chose the large sample set and the wide range of populations to maximize the variation they could capture. The project includes both single-letter differences (single-letter polymorphisms, or SNPs) as well as large differences from the loss, gain or duplication of regions, called copy-number polymorphisms, or CNPs.
“Despite the remarkable achievements following from the Human Genome Project, our knowledge of human genetic variation remains limited. Here we have studied more populations and were able to include CNPs in genomewide studies.
“These results tell us more about human genetic variation and about how to study variation successfully.”
Professor Richard Gibbs Professor of molecular and human genetics at Baylor College of Medicine in Houston, Texas, and director of the BCM Human Genome Research Center
The results show that rarer variants are distributed more unevenly among populations. This might be expected – evolutionary theory implies that the common variants are generally the older ones, having had greater time to spread through a population – but also cautions that genetic studies should include a wide range of population groups to maximise discovery of more recent, population-specific variants.
“The closer we look at human genetic variation, the greater the granularity. An important task in genetics is to discriminate between the variants that are important for health and those that are part of the background.
“This new version of the HapMap will help us design ways to do that – to sort the wheat from the chaff.”
Professor Manolis Dermitzakis From the University of Geneva and one of the project coordinators, and formerly at the Wellcome Trust Sanger Institute
In addition to the genotyping studies described above, HapMap 3 also sequenced ten segments of 100,000 bases from well-characterized regions of the human genome. Unlike discovery using DNA chips – as used in most studies to date – direct sequencing is not biased towards more common variants, but gives a direct estimate of the frequencies of variants.
The researchers found that most variants were relatively uncommon (found in less than one person in ten), but they also found a large number of rare variants (each found in less than one in 100 people) or ‘private’ variants (found in only one person). Almost eight of ten variants were new and almost four of ten of those seen in less than one in 100 people were found in only one population.
From the results, the researchers suggest that variants in some genes, including genes involved in the immune system, wound healing and sense of smell, are under selection in different populations. These genes can now be studied to learn about how these systems work and about disease resistance. These findings show the value of having large studies that include many populations and samples to achieve comprehensive understanding of human variation.
“Some have talked about how little has come from the Human Genome Project over the past 10 years, but perhaps they forget how little we knew then. It is amazing that we have gone from a genome less than 90 per cent completed to looking at genetic changes in one in 200 people or rarer. A few years ago, we had no idea of the extent of structural variation or how we might sample variants present at low frequency.
“The HapMap and other large-scale projects have transformed our understanding of the human genome and its relation to health and disease.”
Professor David Altshuler of Massachusetts General Hospital in Boston and the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University in Cambridge Massachusetts
The HapMap 3/ENCODE 3 data set is publicly available at http://www.hapmap.org.
More information
Dedication
This research is dedicated to Leena Peltonen for her vital leadership role in this study, and in memory of a valued friend and colleague. Professor Peltonen died in March 2010.
Participating Centres
- A full list of participating centres can be seen at the Nature website.
The HapMap Consortium
Details of the project and participants can be accessed at http://hapmap.ncbi.nlm.nih.gov/
Project Funding
The USA National Institutes of Health, the National Human Genome Research Institute, the National Institute on Deafness and Other Communication Disorders and the Wellcome Trust supported the majority of this work. Funding was also provided by the Louis-Jeantet Foundation and the NCCR ‘Frontiers in Genetics’ (Swiss National Science Foundation).
Related Contacts
- Fintan Steele, Broad Institute of MIT and Harvard
1-617 714 7150 - Glenna Picton, Baylor College of Medicine
1-713 798 4712
Publications:
Selected websites
The Eli and Edythe L. Broad Institute of MIT and Harvard
The Eli and Edythe L. Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.
Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide.
Baylor College of Medicine (BCM)
Baylor College of Medicine (BCM), Houston, Texas is the only private medical school in the greater southwest and is recognized as a premiere academic health science center known for excellence in education, research and patient care. For 2009, U.S. News and World Report ranked BCM 13th overall among the nation’s top medical schools for research and 7th for primary care. BCM is also listed 13th among all U.S. medical schools for National Institutes of Health funding, and 2nd in the nation in federal funding for research and development in the biological sciences at universities and college by the National Science Foundation. During the reaccreditation proves in March 2007, BCM received “Accreditation with Commendation” for exemplary performance in fulfilling the accreditation requirements as a provider of continuing medical education.
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease.
The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
